Ontogeny of the ovary in polycystic ovary syndrome

Slides:



Advertisements
Similar presentations
Evaluation of cryopreserved ovarian tissue from prepubertal patients after long-term xenografting and exogenous stimulation  Valérie Luyckx, M.D., Sarah.
Advertisements

(Uuhuuh)genesis (Oogenesis)
N.Cem FIÇICIOĞLU, M.D., Ph.D.AA.,MBA. Professor and Director
Shalmali J. Dharma, M. Sc. , Deepak N. Modi, Ph. D. , Tarala D
Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M
Association of abdominal obesity, insulin resistance, and oxidative stress in adipose tissue in women with polycystic ovary syndrome  Li Chen, M.S., Wen.
Hiroshi Tamura, M. D. , Ph. D. , Yasuhiko Nakamura, M. D. , Ph. D
Jong Yeob Choi, Ph. D. , Min Wha Jo, M. S. , Eun Young Lee, M. S
Developmental programming: prenatal testosterone excess disrupts anti-Müllerian hormone expression in preantral and antral follicles  Almudena Veiga-Lopez,
The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study  Jeff G. Wang, M.D., Richard A. Anderson,
Male contraception Fertility and Sterility
REGULATION OF MENSTRUAL CYCLE
MRNA expression pattern of insulin-like growth factor components of granulosa cells and cumulus cells in women with and without polycystic ovary syndrome.
Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin- releasing hormone receptor antagonist in healthy women with normal ovulation.
Small glutamine-rich tetratricopeptide repeat–containing protein alpha is present in human ovaries but may not be differentially expressed in relation.
Ming-hui Chen, M. D. , Tao Li, Ph. D. , Chen-hui Ding, Ph. D
Comparison of gene expression profiles in granulosa and cumulus cells after ovulation induction with either human chorionic gonadotropin or a gonadotropin-releasing.
Patient-tailored ovarian stimulation for in vitro fertilization
Antimüllerian hormone levels decrease in women using combined contraception independently of administration route  Sanna Kallio, M.D., Johanna Puurunen,
Androstenedione induces abnormalities in morphology and function of developing oocytes, which impairs oocyte meiotic competence  Wataru Tarumi, M.Sc.,
Expression of basic fibroblast growth factor and its receptors in human ovarian follicles from adults and fetuses  Avi Ben-Haroush, M.D., M.Sc., Ronit.
Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome 
Guoying Dong, B. S. , Yueshuai Guo, B. S. , Huarong Cao, B. S
Hongli Liu, M. D. , Ph. D. , Xiaofei Xu, M. D. , Ph. D. , Ting Han, M
Mark S. Nanes, M.D., Ph.D., Caleb B. Kallen, M.D., Ph.D. 
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature.
Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels 
Intrafollicular cortisol levels inversely correlate with cumulus cell lipid content as a possible energy source during oocyte meiotic resumption in women.
Expression of growth differentiation factor-9 and bone morphogenetic protein-15 in oocytes and cumulus granulosa cells of patients with polycystic ovary.
FSH receptor, KL1/2, P450, and PAPP genes in granulosa-lutein cells from in vitro fertilization patients show a different expression pattern depending.
Shilla Chatterjee-Chakrabarty, Ph. D. , Brian T. Miller, Ph. D
Western-style diet, with and without chronic androgen treatment, alters the number, structure, and function of small antral follicles in ovaries of young.
Induction of proteinases in the human preovulatory follicle of the menstrual cycle by human chorionic gonadotropin  Katherine L. Rosewell, B.A., Linah.
Shi Ying Jin, Ph. D. , Lei Lei, Ph. D. , Ariella Shikanov, Ph. D
Growth differentiation factor 3 is induced by bone morphogenetic protein 6 (BMP-6) and BMP-7 and increases luteinizing hormone receptor messenger RNA.
Shalmali J. Dharma, M. Sc. , Deepak N. Modi, Ph. D. , Tarala D
Pup birth from mouse oocytes in preantral follicles derived from vitrified and warmed ovaries followed by in vitro growth, in vitro maturation, and in.
The next (re)generation of ovarian biology and fertility in women: is current science tomorrow's practice?  Dori C. Woods, Ph.D., Jonathan L. Tilly, Ph.D. 
Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating.
Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens 
Evelyn E. Telfer, Ph.D., F.S.B., Mary B. Zelinski, Ph.D. 
The role of the endogenous opioid system in polycystic ovary syndrome
Reproductive and metabolic determinants of granulosa cell dysfunction in normal-weight women with polycystic ovary syndrome  Annie A. Guedikian, B.S.,
Effect of rejuvenation hormones on spermatogenesis
Daniel A. Dumesic, M. D. , David R. Meldrum, M. D. , Mandy G
Expression of bone morphogenetic proteins 4 and 7 and their receptors IA, IB, and II in human ovaries from fetuses and adults  Ronit Abir, Ph.D., Avi.
Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.
Elevation of antimüllerian hormone in women with polycystic ovary syndrome undergoing assisted reproduction: effect of insulin  Xing Yan Liu, M.Sc., Yun.
Gene injections of vascular endothelial growth factor and growth differentiation factor-9 stimulate ovarian follicular development in immature female.
Immunohistochemical localization of growth factors after cryopreservation and 3 weeks' xenotransplantation of human ovarian tissue  Anu David, M.Sc.,
Insulin-like growth factor-II (IGF-II), IGF-binding protein-3 (IGFBP-3), and IGFBP-4 in follicular fluid are associated with oocyte maturation and embryo.
Glial cell line–derived neurotrophic factor (GDNF) and its receptors in human ovaries from fetuses, girls, and women  Jacob Farhi, M.D., Asangla Ao, Ph.D.,
Diet-induced maternal obesity alters ovarian morphology and gene expression in the adult mouse offspring  Ying Cheong, M.D., Khaled H. Sadek, M.B.B.S.,
Bone morphogenetic protein-6 stimulates gene expression of follicle-stimulating hormone receptor, inhibin/activin β subunits, and anti-Müllerian hormone.
Exogenous androstenedione induces formation of follicular cysts and premature luteinization of granulosa cells in the ovary  Yuki Okutsu, M.D., Masanori.
Mohamad Irani, M.D., Zaher Merhi, M.D.  Fertility and Sterility 
Comparison of urinary and recombinant follicle-stimulating hormone in in vitro growth, maturation, and fertilization of mouse preantral follicles  Giannina.
Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin  Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.
Human granulosa-lutein cell in vitro production of progesterone, inhibin A, inhibin B, and activin A are dependent on follicular size and not the presence.
Ovarian expression of markers associated with proliferation or apoptosis in women with diminished ovarian reserve  Víctor Vital-Reyes, M.D., M.Sc., Cristina.
Regulation of insulin-like growth factor binding protein secretion by human granulosa luteal cells in a polycystic ovary-like environment  Susanne Greisen,
Paolo Moghetti, M.D.  Fertility and Sterility 
Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions  Kristen Farrell, M.S.,
Aromatase inhibitors for the treatment of endometriosis
Bone morphogenetic protein 7 (BMP-7) increases the expression of follicle-stimulating hormone (FSH) receptor in human granulosa cells  Jia Shi, M.D.,
A new era in ovulation induction
Cem Fiçicioǧlu, M. D. , Tayfun Kutlu, M. D. , Elif Baglam, M. D
Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation  Reshef.
Female Reproductive system:
Leptin role in the rat prostate ventral lobe
Presentation transcript:

Ontogeny of the ovary in polycystic ovary syndrome Daniel A. Dumesic, M.D., JoAnne S. Richards, Ph.D.  Fertility and Sterility  Volume 100, Issue 1, Pages 23-38 (July 2013) DOI: 10.1016/j.fertnstert.2013.02.011 Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Transition of primordial to primary follicles. Embryonic specification of the female gonad and formation of primordial follicles depends on WNT4 and FOXL2. Quiescent primordial follicles leave the resting pool by mechanisms that involve changes in both oocyte (activation of the PI3K pathway) and somatic cell (levels of AMH) functions. Primary follicle formation is independent of gonadotropins but is associated with changes in granulosa cell function and morphology leading to expression of IGF-I/-II, FSHR, AMH, AR, and KL. Changes in oocyte functions lead to the production of the zona pellucida and expression of GDF9. KL and GDF9 coordinate to regulate formation of the theca cell layer. GDF9 also appears to enhance theca cell androgen production, which in turn can increase the expression of FSHR. In PCOS, high levels of insulin and LH may act on cognate receptors in theca cells, once organized, to further increase androgen production. Levels of FSHR (and AMH?) are elevated; however, some data indicate that AMH is lower (262). Large gray circle: oocyte; red line: zona pellucida; small blue circles: granulosa cells; dark blue boxes: theca cells. Oocyte factor and GDF9 signaling is denoted by green arrows; LH and androgen signaling by red arrows and letters; and insulin signaling by purple arrows. Blue arrows indicate that these primary follicles go on to develop into secondary follicles. Fertility and Sterility 2013 100, 23-38DOI: (10.1016/j.fertnstert.2013.02.011) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Transition from primary to secondary/small antral follicles. Granulosa cells proliferate and follicles grow in response to multiple factors including activin, IGF-I, WNT4/5a, and FSH. The transcription factor FOXO1 impacts both follicle growth and follicle atresia (see the text for details). Consequently, as the distance between the oocyte and the theca layer is increased, theca cell production of androgens becomes more dependent on LH and possibly inhibin-α. Levels of AMH increase and negatively regulate FSH action in granulosa cells to prevent premature maturation. In lean PCOS patients, elevated LH and insulin levels increase theca cell androgen production, which enhances FSHR expression and premature differentiation of granulosa cells via induction of aromatase (CYP19a1), LH receptor (LHCGR), and other genes including RUNX2 (102). WNT4/5a may contribute to the enhanced actions of FSH to induce CYP19a1. Enhanced FSH actions override those of elevated AMH. Large gray circle: oocyte; red line: zona pellucida; small blue circles: granulosa cells; large blue circle: normal theca cells; green circle: PCOS theca. Oocyte factor and GDF9 signaling is denoted by green arrows; inhibin by the orange arrow; LH and androgen signaling by red arrows and letters; and insulin signaling by purple arrows and letters. Large blue arrow indicates continued normal follicular growth. Fertility and Sterility 2013 100, 23-38DOI: (10.1016/j.fertnstert.2013.02.011) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Figure 3 Transition from primary to secondary/small antral follicles. In obese PCOS patients, hyperinsulinemia from adiposity-dependent insulin resistance and altered adipogenesis impair follicular development by mechanisms that appear to differ from those in lean PCOS patients. Insulin may have a greater influence than LH on theca, granulosa, and likely oocyte functions. Adipokines also likely alter each cell type within the follicle. Note that insulin receptor (INSR) expression may be elevated in oocytes of PCOS patients compared to non-PCOS patients (205). Cumulus cells of obese PCOS patients also express higher levels of INSR and specific fatty acid binding proteins (FABPs) (102). Theca cells produce elevated levels of androgens, especially DHEA, in response to LH and elevated expression of CYP17A1 and CYP11A1, which are targets of GATA6 and retinoic acid (RA) (47). The PCOS theca cells exhibit increased expression of enzymes controlling RA production and enhanced responses to RA, including steroidogenesis and the target gene TIG1. These responses may be related to cAMP signaling through exchange protein activated by cAMP II (EPAC II). Conversely, PCOS theca cells exhibit reduced expression of WNT signaling and cGMP signaling pathways, but the functional significance of this remains to be determined. Oocyte factor and GDF9 signaling is denoted by green arrows; inhibin by the orange arrow; LH and androgen signaling by red arrows and letters; and insulin signaling by purple arrows and letters. Fertility and Sterility 2013 100, 23-38DOI: (10.1016/j.fertnstert.2013.02.011) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Figure 4 Preovulatory follicles. The hallmarks of preovulatory follicles are the induction of LH receptors (LHCGR) and elevated expression of aromatase (CYP19A1). In obese individuals with PCOS, preovulatory follicles that are selected and ovulate (either in response to weight reduction, exogenous hormone, and/or metformin) express high AMH and remain hyperandrogenic. Thus, despite lowered insulin action or improved adipogenic function to facilitate the growth of follicles that can be ovulated, theca androgen production is central to the PCOS condition. However, direct effects of insulin and/or androgens may harm oocytes at this late stage or earlier stages of follicular development. Oocyte factor and GDF9 signaling is denoted by green arrows; LH and androgen signaling by red arrows and letters; and insulin signaling by purple arrows. Fertility and Sterility 2013 100, 23-38DOI: (10.1016/j.fertnstert.2013.02.011) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions